Literature DB >> 16052746

Androgens and prostate cancer: are the descriptors valid?

Pradip Roy-Burman, Donald J Tindall, Diane M Robins, Norman M Greenberg, Mary J C Hendrix, Suresh Mohla, Robert H Getzenberg, John T Isaacs, Kenneth J Pienta.   

Abstract

The term androgen-independent cancer has now become a misnomer. Given that the androgen receptor can be activated by even low androgen concentrations or via protein modifications or other protein-protein interactions, a growing prostate cancer has the chance of assuming an androgen depletion-independent state, without necessarily bypassing the androgen signaling processes. It is thus suggested that "androgen-independent (AI)" cancer should be more accurately termed "androgen depletion-independent (ADI)" cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052746     DOI: 10.4161/cbt.4.1.1563

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  13 in total

1.  Androgen modulation of coregulator expression in prostate cancer cells.

Authors:  Hannelore V Heemers; Kevin M Regan; Lucy J Schmidt; S Keith Anderson; Karla V Ballman; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2009-01-22

2.  Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Authors:  Helty Adisetiyo; Mengmeng Liang; Chun-Peng Liao; Joseph H Jeong; Michael B Cohen; Pradip Roy-Burman; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2014-09       Impact factor: 6.384

3.  Cancer stem cells and microenvironment in prostate cancer progression.

Authors:  Chun-Peng Liao; Helty Adisetiyo; Mengmeng Liang; Pradip Roy-Burman
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

Review 4.  Androgen action in prostate cancer.

Authors:  Sujit Basu; Donald J Tindall
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

5.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.

Authors:  Jennifer S Davis; Kent L Nastiuk; John J Krolewski
Journal:  Mol Endocrinol       Date:  2011-02-03

6.  Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Authors:  Xiuping Yu; Yongqing Wang; Ming Jiang; Brian Bierie; Pradip Roy-Burman; Michael M Shen; Makoto Mark Taketo; Marcia Wills; Robert J Matusik
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

Review 7.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

8.  Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.

Authors:  Leah S Lyons; Shuyun Rao; Wayne Balkan; Joanne Faysal; Carol A Maiorino; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2007-12-13

9.  Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Authors:  Jian Yang; Shuo Wei; Da-Sheng Wang; Yu-Chieh Wang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2008-03-13       Impact factor: 7.446

10.  Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth.

Authors:  Chih-Rong Shyr; Meng-Yin Tsai; Shuyuan Yeh; Hong-Yo Kang; Yun-Chao Chang; Pei-Ling Wong; Chao-Cheng Huang; Ko-En Huang; Chawnshang Chang
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.